LEXINGTON, Mass. --(BUSINESS WIRE)--Sep. 17, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of an open label clinical trial to evaluate once-daily 24 mg compared to twice-daily 12 mg oral dosing of CTP-543 in patients with alopecia
LEXINGTON, Mass. --(BUSINESS WIRE)--Sep. 12, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present results from its recently completed Phase 2 trial of CTP-543 in patients with moderate-to-severe alopecia areata. These data will be presented in the late breaking
CTP-543 Achieved its Primary Endpoint in the 8 mg and 12 mg Twice-Daily Dosing Cohorts Advancement into Phase 3 Evaluation Planned in 2020 Company to Host Investor Conference Call Today at 8:30 a.m. ET LEXINGTON, Mass. --(BUSINESS WIRE)--Sep. 3, 2019-- Concert Pharmaceuticals, Inc.
LEXINGTON, Mass. --(BUSINESS WIRE)--Aug. 29, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate at the following upcoming investor conferences: The H.C. Wainwright 21st Annual Healthcare Conference on September 9, 2019 at 8:45 a.m.
Conference Call Scheduled Today at 8:30 a.m. EDT LEXINGTON, Mass. --(BUSINESS WIRE)--Aug. 1, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2019. “As we move into the second half of the year, we are advancing our two wholly-owned
LEXINGTON, Mass. --(BUSINESS WIRE)--Jul. 25, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its second quarter 2019 financial results on Thursday, August 1, 2019 , before the U.S. financial markets open. The Company will host a conference call and webcast at
The Company Expects to Initiate a Phase 2 Trial in Patients with Schizophrenia in the Fourth Quarter of 2019 LEXINGTON, Mass. --(BUSINESS WIRE)--Jun. 12, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported positive results from two studies in its Phase 1 program evaluating CTP-692, a
LEXINGTON, Mass. --(BUSINESS WIRE)--Jun. 5, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of an open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata.
LEXINGTON, Mass. --(BUSINESS WIRE)--May 16, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated a second open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata.
LEXINGTON, Mass. --(BUSINESS WIRE)--May 14, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate at the following upcoming investor conferences: The UBS Global Healthcare Conference on May 21, 2019 at 10:00 a.m.